Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

No More Sarepta-Like Development, FDA Officials Say

20 Oct 2016

• By Derrick Gingery

Related Content

Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales

23 Sep 2016

Duchenne Muscular Dystrophy: Second Product Isn't The Charm

15 Jan 2016

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

20 Oct 2016

Accelerated Approval Should Be Less 'Wide Open,' Califf Says

20 Oct 2016

Duchenne Group's Presentation Is Milestone For Patient Involvement

02 May 2016

Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta

23 Sep 2016

Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry

21 Sep 2016

Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template

15 Oct 2016

Related Companies

Sarepta Therapeutics, Inc.

PTC Therapeutics, Inc.

BioMarin Pharmaceutical Inc.

Additional Topics

United States Approvals Clinical Trials Drug Approval Standards Drug Review Regulation BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.